Tech Company Financing Transactions

Aeglea BioTherapeutics Funding Round

Aeglea BioTherapeutics, operating out of Austin, scored $44 million in funding from Lilly Ventures, Novartis Venture Fund and Ally Bridge Group.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
The proceeds from the financing will be used to support the continued development of Aeglea's innovative pipeline of engineered human enzymes that target diseases at the extremes of abnormal metabolism.

Company Information

Company Status
Mailing Address
901 S. MoPac Expy. Barton Oaks Plz. One 250
Austin, TX 78746
Email Address
Aeglea BioTherapeutics (NASDAQ: AGLE) is developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.
Aeglea BioTherapeutics LinkedIn Company Profile
Social Media
Aeglea BioTherapeutics Company Twitter Account
Company News
Aeglea BioTherapeutics News
Aeglea BioTherapeutics on Facebook
Aeglea BioTherapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Anthony Quinn
  Anthony Quinn LinkedIn Profile  Anthony Quinn Twitter Account  Anthony Quinn News  Anthony Quinn on Facebook
Chief Financial Officer
Charles York
  Charles York LinkedIn Profile  Charles York Twitter Account  Charles York News  Charles York on Facebook
Chief Medical Officer
James Wooldridge
  James Wooldridge LinkedIn Profile  James Wooldridge Twitter Account  James Wooldridge News  James Wooldridge on Facebook
Chief Operating Officer
Leslie Sloan
  Leslie Sloan LinkedIn Profile  Leslie Sloan Twitter Account  Leslie Sloan News  Leslie Sloan on Facebook
VP - R & D
Scott Rowlinson
  Scott Rowlinson LinkedIn Profile  Scott Rowlinson Twitter Account  Scott Rowlinson News  Scott Rowlinson on Facebook



Browse more venture capital transactions:

Prev: 3/23/2015: Canon U.S.A. venture capital transaction
Next: 3/24/2015: 1366 Technologies venture capital transaction


Share this article


About Database of VC Transactions

We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary